Karyopharm Therapeutics Inc (KPTI) Insider Sharon Shacham Sells 10,000 Shares of Stock

Karyopharm Therapeutics Inc (NASDAQ:KPTI) insider Sharon Shacham sold 10,000 shares of the company’s stock in a transaction on Thursday, October 18th. The stock was sold at an average price of $12.63, for a total value of $126,300.00. Following the transaction, the insider now directly owns 713,510 shares in the company, valued at approximately $9,011,631.30. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website.

Sharon Shacham also recently made the following trade(s):

  • On Monday, October 8th, Sharon Shacham sold 12,500 shares of Karyopharm Therapeutics stock. The stock was sold at an average price of $15.75, for a total value of $196,875.00.
  • On Friday, September 7th, Sharon Shacham sold 12,500 shares of Karyopharm Therapeutics stock. The stock was sold at an average price of $19.31, for a total value of $241,375.00.

Karyopharm Therapeutics stock opened at $11.99 on Tuesday. The firm has a market capitalization of $743.11 million, a price-to-earnings ratio of -4.27 and a beta of 3.75. Karyopharm Therapeutics Inc has a fifty-two week low of $9.00 and a fifty-two week high of $21.71.

Karyopharm Therapeutics (NASDAQ:KPTI) last posted its earnings results on Tuesday, August 7th. The company reported ($0.60) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.81) by $0.21. The firm had revenue of $19.89 million during the quarter, compared to analyst estimates of $5.97 million. Equities research analysts forecast that Karyopharm Therapeutics Inc will post -3.18 EPS for the current fiscal year.

KPTI has been the topic of a number of recent analyst reports. HC Wainwright reaffirmed a “buy” rating and set a $30.00 price objective on shares of Karyopharm Therapeutics in a report on Wednesday, August 29th. BidaskClub lowered Karyopharm Therapeutics from a “buy” rating to a “hold” rating in a report on Saturday, September 29th. Zacks Investment Research raised Karyopharm Therapeutics from a “hold” rating to a “buy” rating and set a $21.00 price objective on the stock in a report on Wednesday, July 25th. Robert W. Baird reaffirmed a “buy” rating and set a $25.00 price objective on shares of Karyopharm Therapeutics in a report on Wednesday, August 8th. Finally, Canaccord Genuity reaffirmed a “buy” rating and set a $27.00 price objective on shares of Karyopharm Therapeutics in a report on Tuesday, August 7th. Three analysts have rated the stock with a hold rating and ten have given a buy rating to the stock. The stock has an average rating of “Buy” and an average price target of $22.90.

A number of institutional investors have recently bought and sold shares of the business. Voya Investment Management LLC grew its holdings in Karyopharm Therapeutics by 24.3% in the second quarter. Voya Investment Management LLC now owns 18,661 shares of the company’s stock valued at $317,000 after purchasing an additional 3,653 shares during the last quarter. Metropolitan Life Insurance Co. NY grew its holdings in Karyopharm Therapeutics by 38.9% in the second quarter. Metropolitan Life Insurance Co. NY now owns 16,275 shares of the company’s stock valued at $277,000 after purchasing an additional 4,556 shares during the last quarter. Wells Fargo & Company MN grew its holdings in Karyopharm Therapeutics by 16.3% in the first quarter. Wells Fargo & Company MN now owns 36,036 shares of the company’s stock valued at $483,000 after purchasing an additional 5,062 shares during the last quarter. New York State Common Retirement Fund grew its holdings in Karyopharm Therapeutics by 23.6% in the first quarter. New York State Common Retirement Fund now owns 37,700 shares of the company’s stock valued at $506,000 after purchasing an additional 7,200 shares during the last quarter. Finally, MetLife Investment Advisors LLC grew its holdings in Karyopharm Therapeutics by 51.1% in the second quarter. MetLife Investment Advisors LLC now owns 23,047 shares of the company’s stock valued at $392,000 after purchasing an additional 7,793 shares during the last quarter. 71.67% of the stock is currently owned by institutional investors.

Karyopharm Therapeutics Company Profile

Karyopharm Therapeutics Inc, a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of drugs directed against nuclear transport and related targets for the treatment of cancer and other diseases. Its lead drug candidate is Selinexor(KPT-330), which is in Phase 2b clinical study in treatments of refractory multiple myeloma; Phase 1b/2 clinical study in combination with backbone treatments for multiple myeloma patients; Phase 2b clinical study in diffuse large B-cell lymphoma; Phase 3 clinical trial in combination with Velcade (bortezomib) and dexamethasone for multiple myeloma patients; and Phase 2/3 clinical study in liposarcoma.

Recommended Story: Should I invest in “strong buy” stocks?

Insider Buying and Selling by Quarter for Karyopharm Therapeutics (NASDAQ:KPTI)

Receive News & Ratings for Karyopharm Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Karyopharm Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply